Loading stock data…
$8.50+0.02 (+0.24%)
Exagen Inc.
Exagen Inc. in the Healthcare sector is trading at $8.50 with a market capitalization of $177M. Wall Street consensus targets $10.29 (7 analysts), implying a +21.0% move over the next 12 months. The stock is currently 30% below its 52-week high of $12.23, remaining 73.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.94M↑ | $17.31M↑ | $16.63M↓ | $17.24M↑ | $17.20M |
| Gross Profit | $12.22M↑ | $10.21M↑ | $9.21M↓ | $10.07M↓ | $10.39M |
| Operating Income | -$1.72M↑ | -$3.41M↑ | -$4.97M↓ | -$3.10M↓ | -$2.63M |
| Net Income | -$3.20M↑ | -$3.97M↑ | -$4.67M↑ | -$7.09M↓ | -$4.44M |
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic...